Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Knee Injury Cohort @ the Kennedy (KICK) study recruited its 142nd participant this week. Chief investigator Fiona Watt reports that the study has entered its final stages of recruitment – it aims tofollow 150 people with recent knee injuries over 5 years. 

Joint injury is a major risk factor for osteoarthritis, with about 50% of those with knee injuries developing the condition; this can be in their 30s or 40s if they have suffered sporting injuries whilst young. Work in the Kennedy Institute laboratories on the immediate effects of joint tissue injury has identified important markers of this response: the KICK study is testing whether measurement of this ‘joint injury response’ can predict the development of osteoarthritis in humans. The initial findings of the study were recently presented at the OARSI World Congress in Paris.

The KICK study is pioneering electronic collection of follow-up data – participants can simply click on an emailed link which allows them to input their answers to questionnaires directly and securely on to the study database. The study hopes to identify new tests to predict osteoarthritis, and targets for new medical treatments to slow or prevent the condition. It works closely with Andrew Williams, leading UK sports knee surgeon and other researchers in the newly-formed Arthritis Research UK Centre for Osteoarthritis Pathogenesis, based at the Kennedy Institute.

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.